CD19 and neoplasm: Patients treated on several CAR T cell clinical trials have exhibited antigen escape in response to therapy [49,50] with the most well-studied example being patients who have previously received anti-CD19 CAR T cell therapy relapsing with CD19 negative tumours [51,52,53].